| $350M | ||
| $172M | ||
| $115M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $60,907 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Gilad Oren | President/CEO | 1 | $25,009 | 0 | $0 | $25,009 |
| Duey Marc | director | 1 | $25,000 | 0 | $0 | $25,000 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 2 | $10,898 | 0 | $0 | $10,898 |
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $60,907 and sold $0 worth of Aprea Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $98,969 and sold $29,583 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gilad Oren (President/CEO) — $25,009. Duey Marc (director) — $25,000. Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) — $10,898.
The last purchase of 28,100 shares for transaction amount of $25,009 was made by Gilad Oren (President/CEO) on 2026‑01‑30.
| 2026-01-30 | Gilad Oren | President/CEO | 28,100 0.4492% | $0.89 | $25,009 | -3.94% | ||
| 2026-01-30 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 5,700 0.0911% | $0.89 | $5,073 | -3.94% | ||
| 2025-12-10 | Duey Marc | director | 21,459 0.4475% | $1.17 | $25,000 | -12.52% | ||
| 2025-12-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 5,000 0.1043% | $1.17 | $5,825 | -12.52% | ||
| 2025-04-03 | Gilad Oren | President/CEO | 5,500 0.1023% | $1.84 | $10,110 | -17.78% | ||
| 2024-10-23 | Gilad Oren | President/CEO | 500 0.0086% | $3.92 | $1,958 | -53.33% | ||
| 2024-10-18 | Sale | Duey Marc | director | 6,462 0.1238% | $4.58 | $29,583 | -58.18% | |
| 2024-10-16 | Duey Marc | director | 30,000 0.8303% | $4.39 | $131,700 | -47.29% | ||
| 2024-10-15 | Gilad Oren | President/CEO | 250 0.0046% | $2.90 | $725 | -39.18% | ||
| 2024-10-14 | Gilad Oren | President/CEO | 1,000 0.0163% | $2.59 | $2,590 | -27.34% | ||
| 2024-10-14 | Duey Marc | director | 190 0.0031% | $2.58 | $490 | -27.34% | ||
| 2024-10-11 | Seizinger Bernd R. | director | 10,000 0.169% | $2.68 | $26,800 | -28.08% | ||
| 2024-10-11 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 50 0.0008% | $2.46 | $123 | -28.08% | ||
| 2024-10-10 | Gilad Oren | President/CEO | 150 0.0024% | $2.54 | $381 | -26.18% | ||
| 2024-10-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 450 0.0074% | $2.61 | $1,175 | -26.18% | ||
| 2024-03-13 | Gilad Oren | President, CEO | 2,000 0.0683% | $7.29 | $14,580 | -31.44% | ||
| 2024-03-13 | Seizinger Bernd R. | director | 6,860 0.2342% | $7.29 | $50,009 | -31.44% | ||
| 2024-03-13 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 1,010 0.0345% | $7.29 | $7,363 | -31.44% | ||
| 2024-03-13 | HENNEMAN JOHN B III | director | 6,860 0.2342% | $7.29 | $50,009 | -31.44% | ||
| 2023-06-07 | Seizinger Bernd R. | director | 6,029 0.1917% | $3.68 | $22,192 | +18.87% |
| Gilad Oren | President/CEO | 373720 3.0181% | $289,221.91 | 7 | 0 | <0.0001% |
| Duey Marc | director | 256155 2.0686% | $198,238.35 | 3 | 1 | <0.0001% |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 33433 0.27% | $25,873.80 | 5 | 0 | <0.0001% |
| Christenson Johan | director | 2366104 19.108% | $1.83M | 1 | 0 | +53.58% |
| HealthCap VII, L.P. | 10 percent owner | 2366104 19.108% | $1.83M | 1 | 0 | +53.58% |
| KDev Investments AB | 10 percent owner | 1992586 16.0916% | $1.54M | 0 | 2 | |
| Redmile Group, LLC | 10 percent owner | 1768718 14.2837% | $1.37M | 1 | 1 | +53.58% |
| Versant Vantage I, L.P. | 10 percent owner | 333333 2.6919% | $257,966.41 | 1 | 0 | +53.58% |
| Versant V Luxco S.a r.l. | 10 percent owner | 333333 2.6919% | $257,966.41 | 1 | 0 | +53.58% |
| 5AM Ventures IV, L.P. | Former 10% holder | 138497 1.1185% | $107,182.83 | 1 | 4 | +53.58% |
| ROCKLAGE SCOTT M | Former 10% holder | 75965 0.6135% | $58,789.31 | 0 | 3 | |
| Seizinger Bernd R. | director | 44730 0.3612% | $34,616.55 | 4 | 0 | <0.0001% |
| HENNEMAN JOHN B III | director | 8139 0.0657% | $6,298.77 | 2 | 0 | +11.07% |
| Magni Guido | director | 6500 0.0525% | $5,030.35 | 1 | 0 | +53.58% |
| SCHADE CHRISTIAN S | President & CEO | 5000 0.0404% | $3,869.50 | 1 | 0 | +53.58% |
| Coiante Scott M | SVP, Chief Financial Officer | 2500 0.0202% | $1,934.75 | 1 | 0 | +53.58% |
| Korbel Gregory Alan | VP of Business Dev't | 500 0.004% | $386.95 | 1 | 0 | +53.58% |
| Attar Eyal C. | SVP, Chief Medical Officer | 200 0.0016% | $154.78 | 1 | 0 | +53.58% |
$6,942,298 | 42 | -10.80% | $6.23M | |
$13,664,154 | 40 | -70.35% | $6.54M | |
$931,435 | 28 | 16.31% | $10.24M | |
Aprea Therapeutics, Inc. (APRE) | $29,645,465 | 28 | 8.09% | $9.58M |
$76,600 | 22 | -37.70% | $11.97M | |
$37,200,153 | 21 | -47.67% | $7.59M | |
$287,718 | 15 | -41.45% | $8.6M | |
$11,777,042 | 10 | -11.94% | $6.49M | |
$176,752 | 10 | -28.86% | $6.56M | |
$120,379 | 10 | -24.48% | $11.74M | |
$13,595,542 | 9 | -16.74% | $8.92M | |
$8,731,108 | 7 | 153.66% | $10.73M | |
$159,974 | 7 | -18.60% | $11.36M | |
$18,186,879 | 4 | 49.41% | $10.52M | |
$726,438 | 4 | -72.85% | $7.48M | |
$28,395 | 3 | 3.48% | $10.26M | |
$16,526,031 | 2 | -0.85% | $8.96M | |
$500,000 | 1 | -22.94% | $10.58M | |
$295 | 1 | -14.11% | $10.6M |
| Increased Positions | 10 | +33.33% | 623,895 | +38.54% |
| Decreased Positions | 12 | -40% | 547,234 | -33.8% |
| New Positions | 5 | New | 582,756 | New |
| Sold Out Positions | 6 | Sold Out | 272,968 | Sold Out |
| Total Postitions | 28 | -6.67% | 2M | +4.74% |
| Aigh Capital Management Llc | $460.00 | 7.7% | 539,300 | 0 | 0% | 2025-09-30 |
| Sphera Funds Management Ltd. | $230.00 | 3.86% | 270,000 | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $176.00 | 2.94% | 205,760 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $135.00 | 2.26% | 158,238 | -15,604 | -8.98% | 2025-09-30 |
| Dafna Capital Management Llc | $117.00 | 1.96% | 137,174 | 0 | 0% | 2025-09-30 |
| Sio Capital Management, Llc | $96.00 | 1.6% | 112,223 | -167,146 | -59.83% | 2025-09-30 |
| Morgan Stanley | $56.00 | 0.94% | 65,808 | +2,477 | +3.91% | 2025-09-30 |
| Geode Capital Management, Llc | $38.00 | 0.64% | 44,616 | +1,479 | +3.43% | 2025-09-30 |
| Bnp Paribas Financial Markets | $15.00 | 0.25% | 17,132 | +1,700 | +11.02% | 2025-09-30 |
| Lpl Financial Llc | $14.00 | 0.23% | 16,052 | -1,000 | -5.86% | 2025-09-30 |